检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]天津市第一中心医院,300192
出 处:《天津医药》2002年第12期738-740,F003,共4页Tianjin Medical Journal
摘 要:目的 :探讨炎症介质与不稳定型冠状动脉疾病 (UCAD)的关系及中西医结合序贯治疗的疗效。方法 :大耳白兔高脂饲料喂7周建立动脉粥样硬化模型后 ,随机分3组 ,中西医结合序贯治疗组 (A组 ) ,西医序贯治疗组 (B组 )和常规治疗组 (C组 )。注射垂体后叶素后6h ,A组依顺序给予阿斯匹林 ,硝酸异山梨酯、低分子肝素钙、降纤酶、参麦注射液及神农33注射液治疗 ;B组除不用参麦注射液及神农33注射液 ,余同A组 ;C组除不用降纤酶 ,余同B组。观察给药前及其后的6h和72h血清白介素 -6(IL -6) ,可溶性细胞间黏附分子 -1(sICAM -1)和血浆纤维蛋白原变化及病理改变。结果 :血清IL -6 ,sICAM -1 ,血浆纤维蛋白原在心肌缺血6h升高 ,在心肌缺血72h显著性升高 ,普通病理和电镜显示A组疗效最佳 ,B组次之 ,C组较差。A组和B组血浆纤维蛋白原水平较C组显著性改善。结论 :IL -6 ,sICAM -1等炎性介质参与了UCAD的发生发展进程 。To explore the relationship between inflammatory mediator and UCAD as well as the curative effect of the integrated traditional Chinese medicine and western medicine(TCM_WM)sequential therapy.Methods:Eighteen antherosclerotic big_ear rabbits were randomly divided into 3 groups after 6 hours of pituitrin injection.Aspirin,isosorbide dinitrate,and hepatin were administrated in group C.Defibrase was given besides the conventional in group B.Based on group B therapy,the others in group A were given shenmai injection and shennong 33 injection.Before and after 6 hours and 72 hours of pituierin injection,serum IL_6,sICAM_1,and plasma fibrinogens as well as pathological changes were respectively observed in each group.Results:Serum IL_6,sICAM_1,and plasma fibriogen increased in each group after 6 hours of putuitrin injection,and significantly increased after 72 hours.The plasma fibrinogens in group A and B were much improved.The therapeutic effect in group A was the best,and worst in group C proved by pathological changes.Conclusion:The inflammatory mediators such as IL_6 and sICAM_1 play a very important role in developing UCAD,TCM_WM sequential therapy can improve the curative effect.
关 键 词:不稳定型冠状动脉疾病 治疗 炎症 中西医结合疗法 UCAD
分 类 号:R543.3[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15